Altaris to Acquire Johnson Matthey’s Health Business
New York, NY—Altaris Capital Partners, LLC (collectively with its affiliates, “Altaris”) announced today that it has entered into an agreement to acquire Johnson Matthey Health (“JM Health”) from Johnson Matthey PLC (LSE: JMAT) for total consideration of £325 million. The acquisition is expected to close in the first half of 2022, subject to customary conditions. Following closing of the transaction, JM Health will be renamed and headquartered in the United States.
JM Health is a leading global developer and manufacturer of specialist and complex active pharmaceutical ingredients for pharma and biotech companies. Founded in 1970, JM Health has approximately 1,000 employees across seven global development and manufacturing sites.
Linklaters LLP and Cleary Gottlieb Steen & Hamilton LLP acted as legal counsel for Altaris. Citibank is serving as financial advisor and Herbert Smith Freehills LLP is acting as legal advisor to Johnson Matthey.
Altaris is a healthcare investment firm with an exclusive focus on building companies that deliver value to the healthcare system through innovation and efficiency. Altaris’ operating companies are addressing some of the most complex problems in the healthcare industry, with the ultimate goal of improving access and outcomes for patients. Since inception in 2003, Altaris has invested in more than 45 healthcare companies that have contributed to advancements in the industry and generated significant value appreciation for investors. Altaris is headquartered in New York City and manages $6.0 billion of equity capital. For more information, please visit www.altariscap.com.